Ionis Pharmaceuticals (IONS) Investor Presentation - Slideshow
Ionis Pharmaceuticals(IONS)2023-05-18 17:49Robust Efficacy Anticipated with Pelacarsen in Phase 3 Lp(a) HORIZON Study QALSODY SOD1-ALS (SOD1) SPINRAZA SMA (SMN2) ION859 Parkinson's disease (LRRK2) ION464 Parkinson's disease and Multiple System Atrophy (alpha-synuclein) ION363 FUS-ALS (FUS) ION541 ALS (ATXN2) ION373 Alexander disease (GFAP) Eplontersen ATTR (TTR) ION582 Angelman syndrome (UBE3A-ATS) Tominersen Huntington's disease (HTT) ION260 Spinocerebellar Ataxia Type 3 (ATXN3) ION306 SMA (SMN2) IONIS-MAPTRx Alzheimer's disease (Tau) 24 MAA Accept ...